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Objectives: To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combi-
nation (FTI) with those of fosfomycin and tobramycin alone against cystic ﬁbrosis (CF) and non-CF
bronchiectasis pathogens.
Methods: Clinical isolates of CF Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus
inﬂuenzae, Stenotrophomonas maltophilia, Burkholderia cepacia complex, Escherichia coli and
Klebsiellia spp. were evaluated by MIC, MBC, post-antibiotic effect (PAE), synergy, time–kill, a rat
pneumonia model and spontaneous mutation frequency (SMF).
Results: FTI showed high activity against E. coli, H. inﬂuenzae, S. aureus and Klebsiella spp. For the
S. aureus strains, 75% of which were methicillin resistant (MRSA), FTI had a lower MIC90 than tobramy-
cin. For P. aeruginosa, FTI had a lower MIC90 than fosfomycin, but tobramycin was more active than
either. Synergy studies showed no antagonism between fosfomycin and tobramycin, and 93% of the
isolates demonstrated no interaction. FTI was rapidly bactericidal and exhibited concentration-
dependent killing in time–kill studies. In the rat pneumonia model, FTI and tobramycin demonstrated
bactericidal killing of P. aeruginosa; both were more active than fosfomycin alone. The SMF for
S. aureus resistance to FTI was 2–4 log10 lower than that for tobramycin and 2–7 log10 lower than that for
fosfomycin. For P. aeruginosa, the FTI SMF was 2–3 log10 lower than that for fosfomycin and 1–2 log10
lower than that for tobramycin.
Conclusions: FTI is a broad-spectrum antibiotic combination with high activity in vitro and in vivo.T h e s e
data suggest FTI could be a potential treatment for respiratory infections caused by Gram-positive and
Gram-negative aerobic bacteria.
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Introduction
Cystic ﬁbrosis (CF) and non-CF bronchiectasis patients are predis-
posed to chronic respiratory infections caused by a variety of bac-
teria including Pseudomonas aeruginosa, Staphylococcus aureus
and non-typeable Haemophilus inﬂuenzae. Stenotrophomonas mal-
tophilia, Achromobacter xylosoxidans and Burkholderia cepacia
complex are also frequent pathogens in CF,
1,2 and Moraxella
catarrhalis, Streptococcus pneumoniae and enteric Gram-negative
bacilli are seen in non-CF bronchiectasis.
3 Extensive use of
intravenous, oral and inhaled antibiotics has improved the survival
of CF patients,
4,5 but has also led to the development of bacterial
resistance.
6,7 There is a clear need for new antibiotics, and novel
approaches including combination drugs should be explored.
An ideal therapy would be delivered directly to the lungs, kill
a broad spectrum of bacteria, have a favourable safety proﬁle and
reduce the development of resistance. A combination antibiotic
consisting of fosfomycin and tobramycin may be an appropriate
addition to the current treatments for the management of respirat-
ory infections. Fosfomycin is a phosphonic acid antibiotic
8 with
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cited.little reported human toxicity when administered parenterally.
9 It
is active against both Gram-positive
10,11 and Gram-negative bac-
teria,
12 and inhibits the ﬁrst step of peptidoglycan biosynthesis in
the bacterial cell wall.
8,9 Both oral (fosfomycin calcium and fos-
fomycin trometamol) and intravenous (fosfomycin disodium)
formulations are available, but only oral fosfomycin trometamol
is approved in the USA for treating uncomplicated urinary
tract infections.
9,13 Parenteral administration of fosfomycin is
sporadically used in the UK to treat CF bacterial respiratory
infections,
6,14 but an aerosol formulation deliverable directly to
the lungs has not yet been developed.
Tobramycin is an aminoglycoside and is highly potent
against Gram-negative bacteria, in particular P. aeruginosa.
15
Tobramycin is rapidly bactericidal and acts by inhibiting bac-
terial protein synthesis.
16 Aerosolized tobramycin (TOBI
w)i s
used for the management of P. aeruginosa respiratory infections
in CF patients.
5 Nephrotoxicity and ototoxicity are adverse reac-
tions associated with tobramycin therapy.
17 The greatest risk
factor for development of toxicity is cumulative exposure to
large doses of tobramycin. Bronchiectasis patients may be at
increased risk of developing tobramycin toxicity because they
receive prolonged and repeated antibiotic therapies over their
lifetime.
18
The purpose of this study was to evaluate the in vitro and
in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combi-
nation (FTI) against bacterial respiratory pathogens seen in the
CF and non-CF bronchiectasis populations, and to compare
them with those of fosfomycin and tobramycin, individually.
S. aureus and P. aeruginosa were the major focus of this work,
both because of their frequency and virulence in bronchiectasis
infections and because, as resistance increases in these two
organisms, treatment becomes problematic.
Materials and methods
Bacterial strains
P. aeruginosa strains from patients with CF (n¼100) were obtained
from the Therapeutics Development Network Center for CF
Microbiology at the Children’s Hospital and Regional Medical
Center (Seattle, WA, USA). B. cepacia (n¼20) complex strains
were obtained from the University of British Columbia (Vancouver,
BC, Canada). Non-CF (respiratory, bloodstream, skin/soft tissue)
P. aeruginosa (n¼60), Enterococcus faecalis (n¼5), E. coli (n¼22),
H. inﬂuenzae (n¼16), Klebsiella spp. (n¼22), M. catarrhalis
(n¼5), S. maltophilia (n¼17), S. aureus (n¼16), S. pneumoniae
(n¼8) and Streptococcus pyogenes (n¼5) strains were obtained
from The Jones Group Laboratories (North Liberty, IA, USA) and
The Clinical Microbiology Institute (Wilsonville, OR, USA).
P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. aureus ATCC
29213, S. pneumoniae ATCC 49619, E. faecalis ATCC 29212 and
H. inﬂuenzae ATCC 49247 served as quality control and reference
strains.
19 An animal-passaged derivative of P. aeruginosa ATCC
27853 (C177) was used in the rat pneumonia studies.
Antibiotics
Fosfomycin disodium, tobramycin sulphate and vancomycin hydro-
chloride were obtained from Sigma-Aldrich (St Louis, MO, USA).
Ciproﬂoxacin hydrochloride was obtained from Cellgro (Herndon,
VA, USA). FTI consisted of a 4:1 ratio (w/w basis) of fosfomycin
and tobramycin. Glucose-6-phosphate (Sigma-Aldrich) was added to
the media at a ﬁnal concentration of 25 mg/L for all in vitro evalu-
ations of fosfomycin and FTI.
19,20
MICs and MBCs
MICs were determined by agar plate dilution and broth microdilu-
tion methods.
19,20 The MIC was deﬁned as the lowest concentration
of antibiotic that prevented visible growth after incubation at 358C
for 18–24 h. FTI MIC values were expressed as the concentration
of both drugs (example, FTI MIC of 8 mg/L¼6.4 mg/L
fosfomycinþ1.6 mg/L tobramycin). Vancomycin and ciproﬂoxacin
MICs were determined only for the S. aureus isolates. MBCs were
determined according to CLSI (formerly NCCLS) guidelines.
21 The
MBC was deﬁned by a  3 log10 decrease in cfu/mL of the original
inoculum.
Chequerboard synergy
Interactions between fosfomycin and tobramycin were determined
by the broth microdilution chequerboard method.
22 Two-fold serial
dilutions bracketing the expected MIC value of both antibiotics
were evaluated. The fractional inhibitory concentration (FIC) was
calculated as the MIC of compound 1 in combination with a second
compound, divided by the MIC of compound 1 alone. An FIC index
(FICI) was calculated for each drug combination as the sum of the
individual FICs of compounds 1 and 2. Synergy was deﬁned as an
FICI of  0.5, no interaction as an FICI .0.5 and  4, and antagon-
ism as an FICI .4. The lowest FICI was used for ﬁnal interpretation
of drug interactions.
Post-antibiotic effect (PAE)
PAE values were determined by the viable plate count method.
23
Bacteria were incubated with antibiotic at 2  the MIC for 1–2 h in
a shaking 358C water bath. Growth controls were included in each
experiment. Following exposure, the cultures were diluted 1:1000
and the cfu/mL determined hourly. The PAE was deﬁned as T–C,
where T is the time required for the viable counts of an
antibiotic-exposed culture to increase 1 log10 cfu/mL above the
counts determined immediately after dilution and C is the corre-
sponding time for the growth control.
Time–kill studies
Time–kill experiments were performed according to CLSI stan-
dards.
21 Antibiotics were evaluated at multiples of the MIC in
cation-adjusted Mueller–Hinton broth (CAMHB) (Remel, Lenexa,
KS, USA). A no-drug control was run in each assay. Bacterial cul-
tures and antibiotic were incubated at 358C in a shaking water bath
and killing activity assessed at 1, 2, 4, 6 and 24 h. Antibiotic con-
centrations that reduced the original inoculum by  3 log10 cfu/mL
were considered bactericidal.
Animal efﬁcacy studies
Animals were handled according to the Guidelines for the Care and
Use of Laboratory Animals.
24 All animal protocols were approved
by an IRB/Ethics Committee. Male Sprague–Dawley rats (180–
200 g) were obtained from Charles River Laboratories (Hollister,
CA, USA) and acclimatized for 5 days prior to use. Animals were
housed individually in ventilated cages, fed Purina Lab Diet ad
libitum and allowed free access to water.
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nia model.
25 Rats were anaesthetized with isoﬂurane, and  10
3 cfu
of P. aeruginosa C177 in a 2% agar solution were instilled into the
lungs with an oral gavage needle. The inoculum was deposited at
the ﬁrst bifurcation and distributed throughout the lungs by inspi-
ration. Animals were allowed to recover for 18 h post-infection.
Each experiment consisted of pre-treatment (n¼5–7), saline control
(n¼5–7) and antibiotic (n¼5–7) groups. Rats were anaesthetized
with isoﬂurane, and 100 mL of antibiotic solution or saline was
instilled into the trachea using a MicrosprayerTM (Penn-Century
Inc., Philadelphia, PA, USA). Antibiotics were administered intratra-
cheally twice daily for 3 days.
Animals were euthanized by intraperitoneal administration of
sodium pentobarbital. The pre-treatment control group was har-
vested 18 h post-infection, and the saline and treatment groups 18 h
after the last antibiotic exposure. Lungs were removed aseptically,
homogenized in sterile normal saline and viable bacteria determined
by the colony count method. Statistical differences between the
saline control group and treatment groups were evaluated by the
Mann–Whitney Rank Sum Test using GraphPad Prism
w software
package version 3.03 (GraphPad Software, Inc., San Diego,
CA, USA).
Single-step resistance
Development of resistance after a single exposure to antibiotic was
determined using four clinical and one reference strain of S. aureus
and P. aeruginosa. Late log-phase cultures (10
9–10
10 cfu) were
spread onto Mueller–Hinton agar (BBL, Sparks, MD, USA) plates
containing 4  the MIC of each antibiotic. The culture plates were
incubated at 358C for 48 h and the number of colonies on each plate
was enumerated manually. The frequency of resistance was calcu-
lated by dividing the number of bacteria growing at the deﬁned anti-
biotic concentration by the number of bacteria in the inoculum.
26
MIC values were calculated for three representative spontaneous
mutants and compared with those for the parental strain.
Results
MICs
Table 1 summarizes the MICs at which 50% (MIC50) and 90%
(MIC90) of the clinical isolates were inhibited. FTI had high
activity against the 16 random S. aureus strains, and moderate
activity against S. pneumoniae, S. pyogenes and E. faecalis.
Twelve of the 16 S. aureus strains were categorized as
methicillin-resistant (MRSA). The FTI MIC50 value (2 mg/L)
was nearly identical to that of vancomycin (1 mg/L) and was
superior to that of ciproﬂoxacin (.4 mg/L) for S. aureus. FTI
was also active against single linezolid-resistant (C059) and
glycopeptide-intermediate S. aureus (GISA) (C060) isolates,
with MICs of 2 and 1 mg/L, respectively.
Among the Gram-negative organisms examined FTI had the
lowest MIC50 for E. coli (0.5 mg/L), H. inﬂuenzae (0.5 mg/L),
Klebsiella spp. (1 mg/L) and P. aeruginosa (non-CF, 4 mg/L;
and CF, 8 mg/L) strains. FTI also had high activity against
M. catarrhalis strains, but poor activity against S. maltophilia
and B. cepacia complex. Against tobramycin-resistant and high
fosfomycin MIC ( 128 mg/L) strains, FTI had MICs compar-
able to that of the most active single antibiotic component.
Tobramycin had the lowest MIC50 and MIC90 values for the CF
(2 and 16 mg/L) and non-CF P. aeruginosa (1 and 128 mg/L)
strains. Fosfomycin had potent activity against S. aureus,
H. inﬂuenzae, E. coli and Klebsiella spp. It showed moderate
activity against P. aeruginosa and S. maltophilia, and poor
activity against B. cepacia complex.
MBCs
FTI and tobramycin were bactericidal against the S. aureus
(100%), S. pneumoniae (100%), P. aeruginosa (100%), E. coli
(100%), Klebsiella spp. (100%) and H. inﬂuenzae (83% and
Table 1. MICs of FTI, tobramycin and fosfomycin for Gram-positive and Gram-negative bacteria
Organism (no. of strains)
MIC (mg/L)
FTI tobramycin fosfomycin
range MIC50 (MIC90) range MIC50 (MIC90) range MIC50 (MIC90)
S. aureus
a (16) 0.5–16 2 (8) 0.125–512 0.5 (256) 0.125–16 2 (4)
S. pneumoniae
a (8) 4–32 ND 16–64 ND 8–32 ND
S. pyogenes
b (5) 16–32 ND 16–64 ND 16–64 ND
E. faecalis
a (5) 32 ND 8–512 ND 32 ND
E. coli
a (22) 0.125–1 0.5 (1) 0.5–1 1 (1) 0.25–4 0.5 (2)
H. inﬂuenzae
a (16)  0.13–4 0.5 (2) 0.5–1 1 (1) 0.25–4 0.5 (2)
Klebsiella spp.
b (22) 0.5–16 1 (8) 0.13–.512 0.13 (16) 0.5–16 4 (16)
M. catarrhalis
a (5) 0.5–1 ND 0.5–1 ND 4–16 ND
P. aeruginosa
a, non-CF (60) 1–256 4 (128) 0.13–.512 1 (128) 1–.512 32 (128)
P. aeruginosa
a, CF (100) 1–128 8 (64) 0.25–.512 2 (16) 4–.512 64 (512)
S. maltophilia
a (17) 8–256 64 (128) 2–.512 64 (256) 32–512 64 (128)
B. cepacia complex
a (20) 0.5–.512 512 (.512) 1–.512 64 (512) 512–.512 .512 (.512)
ND, not determined due to the small number of isolates examined.
aMICs were determined by the agar dilution method.
bMICs were determined by the broth microdilution method.
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831100%, respectively) strains (Table 2). Fosfomycin was bacteri-
cidal against S. aureus (80%), S. pneumoniae (86%),
P. aeruginosa (78%), E. coli (90%), Klebsiella spp. (100%) and
H. inﬂuenzae (83%) strains. FTI and tobramycin had MBC/MIC
ratios  8, suggesting that both antibiotics work by killing bac-
teria rather than by inhibiting bacterial growth.
Chequerboard synergy
No antagonism was seen between fosfomycin and tobramycin
by the chequerboard method for any of the 27 strains tested:
S. aureus, n¼4; P. aeruginosa, n¼17; E. coli, n¼5; and
H. inﬂuenzae, n¼1. The combination was categorized as no
interaction for 25 of the 27 strains (93%), and synergistic for 1
P. aeruginosa strain and 1 E. coli strain.
PAE
FTI had the longest PAE for the three type strains, followed by
tobramycin and fosfomycin (Table 3). FTI had the longest PAE
with S. aureus (3.8 h) followed by P. aeruginosa (3 h) and
E. coli (2.8 h).
Time–kill studies
FTI and tobramycin killed in a concentration-dependent fashion
while fosfomycin killed in a time-dependent fashion against
S. aureus and P. aeruginosa (Figure 1). Against a methicillin-
susceptible S. aureus (MSSA) strain (ATCC 29213), FTI and
tobramycin were bactericidal at 2 mg/L (2  MIC) and 1 mg/L
(2  MIC), respectively. FTI was bactericidal against the MRSA
strain (C354) at 1 mg/L (data not shown). FTI and tobramycin
were rapidly (1–2 h) bactericidal against P. aeruginosa ATCC
27853 at 4 mg/L (1  MIC) and 0.5 mg/L (1  MIC), respectively.
FTI and tobramycin maintained bactericidal killing at 24 h, while
cultures exposed to fosfomycin experienced regrowth.
Animal efﬁcacy studies
In the absence of antibiotic treatment, cfu/lung decreased
,1 log10 at days 4 and 7 post-infection. Intratracheal admin-
istration of FTI showed progressively greater killing of
P. aeruginosa with increasing dose (Figure 2). In subsequent
experiments, complete eradication of the C177 infection was
seen with 5 and 12.5 mg/kg FTI. Tobramycin showed 3 log10
bacterial killing at 2.5 mg/kg. Administration of tobramycin
doses higher than 3 mg/kg resulted in complete eradication of
the P. aeruginosa infection, while doses  0.5 mg/kg did not
result in bacterial killing. A reduction in cfu/lung was not
observed after administration of  10 mg/kg fosfomycin.
Single-step resistance
Table 4 shows the frequencies of spontaneous single-step
mutations leading to antibiotic resistance. Against the ﬁve
S. aureus strains, FTI had a mutation frequency 2–4 log10 less
than tobramycin and 2–7 log10 less than fosfomycin. Against
P. aeruginosa, FTI was superior to tobramycin, but the differ-
ences were  2 log10. Relative to the parent strains, MIC values
of the spontaneous mutants increased 4-, 16- and 32- to
128-fold for FTI, tobramycin and fosfomycin, respectively.
Discussion
This study investigated the in vitro and in vivo antibacterial
activities of FTI, a novel inhaled antibiotic combination.
Fosfomycin was selected as the major component because it is
active against both Gram-positive
10,11 and Gram-negative bac-
teria,
12 is bactericidal
10 and has a good safety proﬁle.
8 However,
fosfomycin kills in a time-dependent fashion,
10 is only moder-
ately active against P. aeruginosa and some of the more resistant
Gram-negative organisms,
12 and has a high mutation frequency
resulting in bacterial resistance in vitro.
26,27 Tobramycin is
rapidly bactericidal, exhibits concentration-dependent killing
activity,
16 is highly active against many resistant Gram-
negatives
15 and has a low prevalence of bacterial resistance.
Tobramycin constitutes the minor component because of the
beneﬁts of reducing the lifetime accumulation of aminoglyco-
side toxicity,
18 which can be minimized by lowering the dose of
tobramycin.
Polymicrobial respiratory infections are a signiﬁcant cause of
morbidity and mortality in CF and non-CF bronchiectasis
patients
2,3 as well as other diseases characterized by chronic
Table 3. PAE of FTI, tobramycin and fosfomycin for S. aureus
P. aeruginosa and E. coli
Organism Antibiotic MIC (mg/L) PAE (h)
S. aureus








b ATCC 25922 FTI 1.0 2.8
tobramycin 0.5 2.5
fosfomycin 2.0 1.0
aPAE was determined after a 2 h exposure to 2  the MIC of antibiotic.
bPAE was determined after a 1 h exposure to 2 the MIC of antibiotic.
Table 2. MBC/MIC ranges of clinical strains




S. aureus (10) 1–2 1–2 1–8
S. pneumoniae (7) 1–4 1–2 1–16
P. aeruginosa, non-CF (10) 1–4 1–2 2–8
P. aeruginosa,CF (8) 1–4 1–4 2–.16
E. coli (10) 1–4 1–4 1–8
Klebsiella spp. (5) 1 1–4 1–4
H. inﬂuenzae (6) 1–8 1–2 1–8
aThe MBC/MIC ratio was calculated by dividing the MBC (mg/L) by the
MIC (mg/L).
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832airway infection. Important pathogens common to both popu-
lations include S. aureus, P. aeruginosa and non-typeable
H. inﬂuenzae. FTI demonstrated excellent activity against both
S. aureus and H. inﬂuenzae. S. aureus may be particularly patho-
genic and the prevalence of MRSA is increasing.
1 We demon-
strated that FTI had high activity against ciproﬂoxacin- and
methicillin-resistant S. aureus, suggesting that it might be a
good therapeutic agent for these infections. Neither CF nor
non-CF P. aeruginosa was found to be as susceptible to FTI as
it was to tobramycin when susceptibility testing was conducted
by CLSI standards.
19 However, in vitro antibiotic activity does
not always correlate with in vivo activity, particularly in CF
because CF sputum has been shown to inhibit the activity of
aminoglycosides.
28,29 FTI demonstrated relatively poor activity
against other CF pathogens, particularly S. maltophilia and
B. cepacia complex. However, it was active against other
non-CF bronchiectasis pathogens including M. catarrhalis,
E. coli, Klebsiella and S. pneumoniae.
Examination of synergy by the chequerboard method demon-
strated no interaction between fosfomycin and tobramycin for
the majority of clinical P. aeruginosa, E. coli and S. aureus
strains. Antagonism was not observed, while synergy was
detected in 7% of the strains. To our knowledge this is the ﬁrst
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Figure 1. Time–kill curves for P. aeruginosa ATCC 27853 and (a) FTI, (b) fosfomycin and (c) tobramycin, and for S. aureus ATCC 29213 and (d) FTI,
(e) fosfomycin and (f) tobramycin. Antibiotics were tested at concentrations of 0.5  MIC (asterisks), 1  MIC (open triangles), 2  MIC (open circles),
4 MIC (open squares), 8  MIC (ﬁlled triangles) and 16  MIC (ﬁlled circles). Closed squares, no drug; broken line, bactericidal line.
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833tobramycin. Our results were consistent with those reported
between fosfomycin and other aminoglycosides.
30,31 The PAE of
FTI was superior to that of fosfomycin and tobramycin for all
three bacterial species. These data were consistent with time–
kill kinetics, which also demonstrated slower bacterial regrowth
with FTI compared with tobramycin or fosfomycin.
Time–kill experiments were conducted to evaluate the rate
and degree of bacterial killing. FTI and tobramycin were rapidly
bactericidal against P. aeruginosa and S. aureus. FTI killed
in a concentration-dependent fashion, which is somewhat
surprising because fosfomycin, the major component of the
combination, killed in a time-dependent fashion.
10 Tobramycin
killed in a concentration-dependent fashion like other aminogly-
coside antibiotics.
16 We also demonstrated that fosfomycin was
bactericidal against S. aureus, which is consistent with previous
studies.
10 Fosfomycin’s mechanism of killing against
P. aeruginosa is not well characterized. This study demonstrates
that bactericidal killing is not reached at concentrations  16 
the fosfomycin MIC for P. aeruginosa ATCC 27853. MBC
experiments also conﬁrmed that FTI reached bactericidal killing
against clinical P. aeruginosa, S. aureus and E. coli strains.
The in vitro studies with FTI were supported by animal
efﬁcacy experiments in rats. Lung cfus were stable over the
treatment period (3 days) and demonstrated that bacterial killing
was due to the activity of the antibiotics (data not shown).
P. aeruginosa colony counts in rat lung dropped at least 3 log10
with treatment and the organisms were eradicated with higher
doses of FTI. While the in vivo activity of FTI is slightly less
than that of tobramycin on a weight basis, tobramycin accounts
for only 20% of FTI. The tobramycin MIC for C177 (0.5 mg/L)
is 8-fold less than the FTI MIC (4 mg/L) and may explain the
slight difference in activity. Fosfomycin alone has very little
activity against P. aeruginosa in vivo and conﬁrms the in vitro
data presented in this study.
Development of antibiotic resistance is of particular concern
in bronchiectasis patients. Antibiotic options are limited and
bacterial isolates, particularly those from CF individuals, are
resistant to many of the currently approved antibiotics.
2
Combinations of antibiotics administered independently (parent-
eral or parenteralþoral) are commonly used to treat multidrug-
resistant P. aeruginosa during exacerbations,
31,32 and to slow the
development of resistance.
2 Therefore, it would also seem prom-
ising to combine fosfomycin and tobramycin in the same
aerosol formulation if the combination shows a clinically
relevant beneﬁt such as slowing the development of resistance.
The spontaneous mutation frequency resulting in resistance after
a single exposure was dramatically less than the frequencies of
fosfomyin or tobramycin for S. aureus and P. aeruginosa.

























































Figure 2. Reduction of P. aeruginosa (strain C177) cfu in the rat lung after
intratracheal administration of antibiotic twice daily for 3 days. (a) FTI.
(b) Tobramycin. (c) Fosfomycin. Data are expressed as means+SD.
*P,0.05; **P,0.01. PreTx, pre-treatment.
















































834Fosfomycin resistance occurred very rapidly after a single
in vitro exposure, in our studies. This ﬁnding is consistent with
previous reports.
26 However, evidence for the in vivo develop-
ment of fosfomycin resistance is lacking. Fosfomycin has been
extensively used for .20 years in Japan and Europe for the
treatment of urinary tract infections. Despite this, the reported
fosfomycin resistance in urinary E. coli isolates remains ,2%.
13
Antibiotic options for CF or non-CF bronchiectasis patients are
limited. FTI, a novel antibiotic combination, has many desirable
properties. Pre-clinical research demonstrates that FTI is active
against important CF and non-CF respiratory pathogens including
S. aureus, H. inﬂuenzae, M. catarrhalis, coliforms and multidrug-
resistant P. aeruginosa. FTI was rapidly bactericidal and had
activity comparable to that of tobramycin. Moreover, FTI reduced
the development of antibiotic resistance. Fosfomycin, the major
component of FTI, has a very favourable safety proﬁle when
administered parenterally.
9 Additionally, several studies have
shown that fosfomycin reduces aminoglycoside-induced nephro-
toxicity.
33–35 Since tobramycin constitutes 20% of FTI on a
weight basis, the cumulative toxic effects due to tobramycin could
also be reduced. The comparative safety of FTI should ultimately
be evaluated in future studies in the affected populations. These
data suggest that FTI should be investigated further for the
treatment of CF and non-CF bronchiectasis infections.
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